Beijing Chunlizhengda Medical Instruments Future Growth
Future criteria checks 5/6
Beijing Chunlizhengda Medical Instruments is forecast to grow earnings and revenue by 31.2% and 29.8% per annum respectively. EPS is expected to grow by 31.9% per annum. Return on equity is forecast to be 13.2% in 3 years.
Key information
31.2%
Earnings growth rate
31.9%
EPS growth rate
| Medical Equipment earnings growth | 36.2% |
| Revenue growth rate | 29.8% |
| Future return on equity | 13.2% |
| Analyst coverage | Low |
| Last updated | 09 May 2024 |
Recent future growth updates
Recent updates
Beijing Chunlizhengda Medical Instruments' (HKG:1858) Upcoming Dividend Will Be Larger Than Last Year's
Jul 01
The Returns On Capital At Beijing Chunlizhengda Medical Instruments (HKG:1858) Don't Inspire Confidence
May 25We Think You Can Look Beyond Beijing Chunlizhengda Medical Instruments' (HKG:1858) Lackluster Earnings
Apr 04Beijing Chunlizhengda Medical Instruments Co., Ltd.'s (HKG:1858) Shareholders Might Be Looking For Exit
Jan 06Returns On Capital At Beijing Chunlizhengda Medical Instruments (HKG:1858) Paint A Concerning Picture
Dec 06Returns On Capital At Beijing Chunlizhengda Medical Instruments (HKG:1858) Paint A Concerning Picture
Aug 31Here's What's Concerning About Beijing Chunlizhengda Medical Instruments' (HKG:1858) Returns On Capital
Apr 11Here's What To Make Of Beijing Chunlizhengda Medical Instruments' (HKG:1858) Decelerating Rates Of Return
Dec 05Returns On Capital At Beijing Chunlizhengda Medical Instruments (HKG:1858) Have Hit The Brakes
Apr 28I Built A List Of Growing Companies And Beijing Chunlizhengda Medical Instruments (HKG:1858) Made The Cut
Dec 30Beijing Chunlizhengda Medical Instruments (HKG:1858) Could Become A Multi-Bagger
Dec 06Is Now The Time To Put Beijing Chunlizhengda Medical Instruments (HKG:1858) On Your Watchlist?
Sep 24We Like Beijing Chunlizhengda Medical Instruments' (HKG:1858) Returns And Here's How They're Trending
Sep 06We Take A Look At Whether Beijing Chunlizhengda Medical Instruments Co., Ltd.'s (HKG:1858) CEO May Be Underpaid
Jun 15Here's Why We Think Beijing Chunlizhengda Medical Instruments (HKG:1858) Is Well Worth Watching
Jun 05Beijing Chunlizhengda Medical Instruments (HKG:1858) Could Become A Multi-Bagger
May 09Beijing Chunlizhengda Medical Instruments Co., Ltd. Just Beat EPS By 5.1%: Here's What Analysts Think Will Happen Next
Apr 01What Type Of Shareholders Make Up Beijing Chunlizhengda Medical Instruments Co., Ltd.'s (HKG:1858) Share Registry?
Feb 22Beijing Chunlizhengda Medical Instruments (HKG:1858) Is Very Good At Capital Allocation
Feb 07
Here's Why I Think Beijing Chunlizhengda Medical Instruments (HKG:1858) Is An Interesting Stock
Jan 25Estimating The Intrinsic Value Of Beijing Chunlizhengda Medical Instruments Co., Ltd. (HKG:1858)
Jan 10Did You Participate In Any Of Beijing Chunlizhengda Medical Instruments' (HKG:1858) Incredible 713% Return?
Dec 28Should You Rely On Beijing Chunlizhengda Medical Instruments's (HKG:1858) Earnings Growth?
Dec 16Declining Stock and Solid Fundamentals: Is The Market Wrong About Beijing Chunlizhengda Medical Instruments Co., Ltd. (HKG:1858)?
Dec 04Here's What We Learned About The CEO Pay At Beijing Chunlizhengda Medical Instruments Co., Ltd. (HKG:1858)
Nov 21Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,382 | 547 | 466 | 462 | 2 |
| 12/31/2025 | 1,907 | 430 | 327 | 349 | 2 |
| 12/31/2024 | 1,497 | 336 | 114 | 232 | 2 |
| 6/30/2024 | 1,048 | 231 | 446 | 482 | N/A |
| 3/31/2024 | 1,184 | 277 | 457 | 502 | N/A |
| 12/31/2023 | 1,209 | 278 | 478 | 512 | N/A |
| 9/30/2023 | 1,234 | 279 | 129 | 131 | N/A |
| 6/30/2023 | 1,171 | 277 | 67 | 84 | N/A |
| 3/31/2023 | 1,191 | 290 | -64 | -59 | N/A |
| 12/31/2022 | 1,202 | 308 | 16 | 41 | N/A |
| 9/30/2022 | 1,150 | 328 | -43 | 30 | N/A |
| 6/30/2022 | 1,197 | 324 | -49 | 64 | N/A |
| 3/31/2022 | 1,139 | 328 | -34 | 134 | N/A |
| 12/31/2021 | 1,108 | 322 | -35 | 165 | N/A |
| 9/30/2021 | 984 | 287 | -10 | 177 | N/A |
| 6/30/2021 | 1,013 | 322 | 137 | 256 | N/A |
| 3/31/2021 | 1,007 | 318 | 227 | 303 | N/A |
| 12/31/2020 | 938 | 283 | 237 | 261 | N/A |
| 9/30/2020 | 913 | 264 | 173 | 249 | N/A |
| 6/30/2020 | 887 | 244 | 109 | 238 | N/A |
| 3/31/2020 | 826 | 216 | 69 | 191 | N/A |
| 12/31/2019 | 855 | 237 | 99 | 232 | N/A |
| 9/30/2019 | 758 | 201 | 68 | 161 | N/A |
| 6/30/2019 | 660 | 164 | 37 | 91 | N/A |
| 3/31/2019 | 579 | 135 | 47 | 100 | N/A |
| 12/31/2018 | 498 | 106 | 56 | 109 | N/A |
| 9/30/2018 | 444 | 94 | 72 | 111 | N/A |
| 6/30/2018 | 389 | 83 | 87 | 113 | N/A |
| 3/31/2018 | 345 | 76 | N/A | 102 | N/A |
| 12/31/2017 | 300 | 68 | N/A | 90 | N/A |
| 9/30/2017 | 261 | 65 | N/A | 86 | N/A |
| 6/30/2017 | 221 | 63 | N/A | 82 | N/A |
| 3/31/2017 | 215 | 63 | N/A | 73 | N/A |
| 12/31/2016 | 208 | 63 | N/A | 65 | N/A |
| 9/30/2016 | 201 | 55 | N/A | 46 | N/A |
| 6/30/2016 | 195 | 47 | N/A | 27 | N/A |
| 3/31/2016 | 186 | 43 | N/A | 13 | N/A |
| 12/31/2015 | 177 | 38 | N/A | -1 | N/A |
| 9/30/2015 | 179 | 47 | N/A | 7 | N/A |
| 6/30/2015 | 163 | 44 | N/A | -16 | N/A |
| 3/31/2015 | 149 | 41 | N/A | 4 | N/A |
| 12/31/2014 | 135 | 37 | N/A | 24 | N/A |
| 9/30/2014 | 129 | 37 | N/A | 40 | N/A |
| 12/31/2013 | 111 | 33 | N/A | 28 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1858's forecast earnings growth (31.2% per year) is above the savings rate (2.3%).
Earnings vs Market: 1858's earnings (31.2% per year) are forecast to grow faster than the Hong Kong market (10.9% per year).
High Growth Earnings: 1858's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 1858's revenue (29.8% per year) is forecast to grow faster than the Hong Kong market (7.5% per year).
High Growth Revenue: 1858's revenue (29.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1858's Return on Equity is forecast to be low in 3 years time (13.2%).